NYSE:AYI
ACUITY INC. (DE)
A leading integrator of robotics and software platforms that automates complex life science workflows to accelerate drug discovery and clinical trials.
Key Metrics
Investment Thesis
Bull Case
ACUITY is well-positioned to capture long-term secular growth in the life sciences sector as pharma companies aggressively pursue asset-light strategies by outsourcing complex lab automation. The company's recurring revenue model from service contracts provides visibility into future cash flows, cushioning it against one-time project volatility. Strong balance sheet metrics with $422.5M in cash and equivalents allow for strategic M&A to expand market share and diversify the product portfolio.
Bear Case
Recent net income trends show a slight contraction from 2024 to 2025, potentially signaling margin pressure or one-time charges related to acquisitions that could persist. The massive cash outflow from investing activities of $1.28B in the latest period raises concerns about liquidity if acquisition targets become scarce or deal terms worsen. High levels of goodwill and intangible assets ($1.50B and $1.10B respectively) present an impairment risk if the life sciences market undergoes a downturn.
About ACUITY INC. (DE)
ACUITY INC. (AYI) is a global provider of intelligent automation solutions for life sciences research and development, serving pharmaceutical, biotechnology, and CRO markets with high-throughput laboratory robotics and software.
Analysis
Management Discussion
In 2025, ACUITY reported revenue of $4.35B, representing growth from the previous year, while net income remained resilient at $396.6M despite a large $1.19B acquisition activity that drove significant cash outflows for investing activities. The company maintained strong operating cash flow of $601.4M, indicating healthy conversion of earnings, though it also utilized over $118M in share repurchases and paid dividends to shareholders. The substantial increase in accounts receivable suggests robust sales volume, while the heavy capital expenditures reflect ongoing investments in manufacturing capacity and R&D.
Industry Overview
The laboratory automation industry is experiencing a structural shift from manual, low-throughput methods to fully integrated, software-defined robotic platforms driven by the need for faster drug discovery. Major players are converging as traditional equipment makers add software capabilities while pure-play software firms develop proprietary hardware partnerships. This consolidation trend favors companies with end-to-end solutions that can manage the entire workflow rather than just isolated components.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $3.95B | $3.84B | $4.35B |
| Cost of Revenue | $2.24B | $2.06B | $2.27B |
| Gross Profit | $1.71B | $1.78B | $2.08B |
| Operating Expenses | $1.24B | $1.23B | $1.51B |
| Operating Income | $473.4M | $553.3M | $563.9M |
| R&D | $97.1M | $102.3M | $140.2M |
| G&A | $1.21B | $1.23B | $1.48B |
| Stock-Based Comp | $42.0M | $46.6M | $45.1M |
| D&A | $93.2M | $91.1M | $133.1M |
| Depreciation | $51.1M | $51.4M | $56.6M |
| Amortization | $42.1M | $39.7M | $76.5M |
| Other OpEx | $-70.2M | $-102.3M | $-110.5M |
| Non-Operating Income | $-26.7M | $-4.7M | $-63.7M |
| Interest Expense | $27.9M | — | — |
| Interest Income | $9.0M | $29.8M | $20.5M |
| Pre-Tax Income | $446.7M | $548.6M | $500.2M |
| Income Tax | $100.7M | $126.0M | $103.6M |
| Continuing Ops | $346.0M | $422.6M | $396.6M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $346.0M | $422.6M | $396.6M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $346.0M | $422.6M | $396.6M |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Current Assets | $1.40B | $1.87B | $1.65B |
| Cash & Equivalents | $397.9M | $845.8M | $422.5M |
| Accounts Receivable | $555.3M | $563.0M | $593.9M |
| Inventory | $368.5M | $387.6M | $526.7M |
| Prepaid Expenses | $73.5M | $75.1M | $108.4M |
| Other Current Assets | $0 | $0 | $0 |
| Long-Term Assets | $2.01B | $1.94B | $3.10B |
| PP&E (Net) | $297.6M | $303.9M | $343.2M |
| Intangibles | $481.2M | $440.5M | $1.10B |
| Goodwill | $1.10B | $1.10B | $1.50B |
| Operating Leases | $84.1M | $65.6M | $97.4M |
| Other LT Assets | $52.5M | $34.4M | $68.6M |
| Total Assets | $3.41B | $3.81B | $4.76B |
| Current Liabilities | $595.4M | $687.9M | $845.8M |
| Accounts Payable | $285.7M | $352.3M | $454.5M |
| Current Leases | $19.7M | $19.2M | $23.3M |
| Deferred Revenue | $14.1M | $17.4M | $21.4M |
| Other Current Liab | $275.9M | $299.0M | $346.6M |
| Long-Term Liabilities | $797.7M | $747.9M | $1.18B |
| Long-Term Debt | $495.6M | $496.2M | $896.8M |
| LT Operating Leases | $75.5M | $58.1M | $84.3M |
| Other LT Liab | $179.0M | $152.1M | $165.4M |
| Total Liabilities | $1.39B | $1.44B | $2.03B |
| Shareholders' Equity | $2.02B | $2.38B | $2.72B |
| Retained Earnings | $3.51B | $3.91B | $4.29B |
| AOCI | $-112.6M | $-114.9M | $-76.5M |
| Total L&E | $3.41B | $3.81B | $4.76B |
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Net Income (CFO) | $346.0M | $422.6M | $396.6M |
| Non-Cash Adjustments | $565.8M | $153.7M | $100.0M |
| Working Capital Changes | $-333.7M | $42.9M | $104.8M |
| Cash from Operations | $578.1M | $619.2M | $601.4M |
| Capital Expenditures | $66.7M | $64.0M | $68.4M |
| Cash from Investing | $-90.7M | $-65.1M | $-1.28B |
| Debt Issuances | $0 | — | $600.0M |
| Debt Repayments | $0 | — | $200.0M |
| Share Buybacks | $266.6M | $88.7M | $118.5M |
| Dividends Paid | $16.8M | $18.2M | $20.6M |
| Cash from Financing | $-312.9M | $-104.5M | $255.4M |
| FX Effect | $200.0K | $-1.7M | $600.0K |
| Net Change in Cash | $174.7M | $447.9M | $-423.3M |
| Beginning Cash | $223.2M | $397.9M | $845.8M |
| Ending Cash | $397.9M | $845.8M | $422.5M |
Frequently Asked Questions
How does ACUITY INC. (DE) make money?
The company's revenue is driven primarily by its integration of proprietary robotic systems and advanced workflow automation software into custom solutions for high-throughput screening and assay development. Additional segments include maintenance contracts, spare parts sales, and professional services related to system installation and training. The business model relies on a mix of upfront equipment sales and recurring service revenue streams.
What are the main risks for AYI?
The life sciences sector is highly sensitive to biotech funding cycles, meaning any reduction in venture capital or public market valuations could directly impact ACUITY's order book and revenue growth. The company faces intense competition from both traditional laboratory equipment giants expanding into robotics and emerging software-only competitors disrupting the integrated automation market. Currency exchange rate fluctuations pose a material risk given the company's significant international operations, particularly in Europe and Asia. Dependence on key personnel with specialized knowledge of complex robotic systems creates operational concentration risks.
What is AYI's competitive advantage?
ACUITY holds significant moats through its proprietary software platforms that tightly integrate with hardware, creating high switching costs for customers who have built extensive data ecosystems around the automation. The company benefits from first-mover advantages in specific niche workflows within life sciences where it has accumulated deep domain knowledge and patented technologies. Its ability to offer scalable, cloud-connected solutions provides a competitive edge against legacy laboratory equipment manufacturers.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.